Detailed Information
Cited 1 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results863O - Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results
- Other Titles
- 863O - Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results
- Authors
- Gross-Goupil, M[Gross-Goupil, M.]; Kwon, TG[Kwon, T. G.]; Eto, M[Eto, M.]; Ye, D[Ye, D.]; Miyake, H[Miyake, H.]; Seo, SI[Seo, S. I.]; Byun, SS[Byun, S. S.]; Lee, JL[Lee, J. L.]; Master, V[Master, V.]; Jin, J[Jin, J.]; Debenedetto, R[Debenedetto, R.]; Linke, R[Linke, R.]; Casey, M[Casey, M.]; Rosbrook, B[Rosbrook, B.]; Frean, MJL[Frean, M. J. Lechuga]; Valota, O[Valota, O.]; Grande, E[Grande, E.]; Quinn, DI[Quinn, D. I.]
- Issue Date
- Oct-2018
- Publisher
- OXFORD UNIV PRESS
- Citation
- ANNALS OF ONCOLOGY, v.29, no.8, pp.303 - 303
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANNALS OF ONCOLOGY
- Volume
- 29
- Number
- 8
- Start Page
- 303
- End Page
- 303
- ISSN
- 0923-7534
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.